This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Amphotericin parenteral

Updated 2 Feb 2023 | Polyene antifungals


Powder for concentrate for solution for infusion containing amphotericin

Drugs List

  • amphotericin 50mg powder for concentrate for solution for infusion
  • FUNGIZONE 50mg powder for concentrate for solution for infusion
  • Therapeutic Indications


    Aspergillosis: treatment
    Coccidioidomycosis: treatment
    Cryptococcosis - treatment
    Disseminated candidosis: treatment
    Mucormycosis: treatment
    North American blastomycosis: treatment
    Serious fungal infections



    Initially 250micrograms/kg daily, increasing gradually to 1mg/kg daily depending on individual response and tolerance.

    Within the range of 250micrograms/kg to 1mg/kg the daily dose should be maintained at the highest level which is not accompanied by unacceptable toxicity.

    If medication is interrupted for more than seven days, therapy should be resumed starting at the lowest dosage level (i.e. 250micrograms/kg, and increased gradually).

    Severe infection:
    The daily dose may be gradually increased up to a maximum of 1.5mg/kg.
    As amphotericin is excreted slowly, the higher doses may be given on alternate days.
    Several months of therapy are usually necessary. Shorter durations of therapy may produce inadequate response and relapse.
    A total daily dose of 1.5mg/kg must NOT be exceeded.


    (See Dosage; Adult)


    Systemic fungal infections (unlicensed)
    1mg/kg once daily. Increase if necessary to 1.5mg/kg daily.
    After seven days, may be reduced to 1mg/kg to 1.5mg/kg on alternate days.

    Additional Dosage Information

    Test dose
    Severe infusion-related reactions can occur during administration, therefore it is advisable to give a test dose before a new course of treatment.
    For this purpose, give a small amount of the infusion (e.g. 1mg in adults or 100micrograms/kg (up to a maximum 1mg) in children) over 20 to 30 minutes. Stop the infusion and observe the patient for the next 30 minutes.
    If there have been no severe allergic or anaphylactic reactions, the infusion can be continued.
    It must be noted that the patient's response to the test dose may not be indicative of subsequent severe side effects.

    For patients who experience an acute and fast development of the fungal infection, and have good lung function as well as having good tolerance to the test dose with no serious side effects, administer 0.3mg/kg amphotericin B intravenously within the period of 2 to 6 hours. If patients experience serious side effects to the test dose or they suffer cardiopulmonary impairment, the suggested dose would be of 5mg to 10mg.

    The dose can be increased by 5mg to 10mg daily to a maximum of 0.5mg/kg to 1mg/kg daily.

    Other routes used
    (In adult patients)
    The use of amphotericin infusion by other routes has been documented:

    Bladder irrigation/instillation (e.g. candiduria)
    Continuous irrigation with 50mg amphotericin in 1 litre of sterile water daily until urinary cultures are negative.
    Intermittent use of volumes of 100ml to 400ml (concentrations of 37.5micrograms/ml to 200micrograms/ml) have also been used.
    The urine should be alkalinised (with potassium citrate) and antifungal ointment applied to the perineal area.

    Lung inhalation (e.g. pulmonary aspergillosis)
    8mg to 40mg amphotericin, nebulised in sterile water or glucose 5%, administered daily in divided doses.
    Concurrent eradication of oral and intestinal yeast reservoirs is recommended.

    Intrathecal (e.g. coccidioidal meningitis)
    The intrathecal dosage of amphotericin normally ranges between 100micrograms and 1.5mg per dose, administered at intervals ranging from daily to weekly, beginning at a low dosage and increasing the dosage until the appearance of patient intolerance.
    Amphotericin is irritating when injected into the cerebrospinal fluid.
    Solutions containing amphotericin have also been administered by local instillation for the treatment of fungal infections of the ear, eye, peritoneum, lung cavities and joint spaces.


    For intravenous infusion. Recommended concentration for intravenous infusion is 10 mg/100ml.

    Bladder irrigation/instillation.
    Intrathecal injection.
    Local instillation.


    Long QT syndrome
    Torsade de pointes

    Precautions and Warnings

    Family history of long QT syndrome
    Prior total body irradiation
    Electrolyte imbalance
    History of torsade de pointes
    Renal impairment

    Correct electrolyte disorders before treatment
    Avoid within 14 days of discontinuing sodium stibogluconate
    May be used for hypersensitive patients only in life threatening situations
    Treatment to be initiated by specialist
    Different preparations of intravenous amphotericin are not interchangeable
    Initial test dose should be given
    Consider monitoring ECG in patients at risk of QT prolongation
    Monitor full blood count regularly
    Monitor hepatic function regularly
    Monitor renal function regularly
    Monitor serum electrolytes
    Monitor serum magnesium regularly
    Monitor serum potassium regularly
    Discontinue if liver function tests become abnormal
    Reduce dose and/or interrupt therapy if renal impairment worsens

    It is essential to verify the product name and the dosage before administration to avoid overdose.

    There is a risk of confusion between non-lipid formulations and lipid formulations of injectable amphotericin.

    Care should be taken in the selection and administration of intravenous amphotericin preparations, especially with regard to dose calculations.

    Severe infusion-related reactions, can occur during administration of amphotericin containing products.

    Serum creatinine levels exceeding 260 micromole/litre, require product discontinuation or dosage reduction until renal function improves

    While some patients may tolerate full intravenous doses of amphotericin without difficulty, most will exhibit some intolerance particularly during the initiation of therapy.

    In patients experiencing adverse reactions these may be made less severe by giving aspirin, other antipyretics, antihistamines or anti-emetics.
    Pethidine has been used in some patients to decrease the duration or intensity of shaking, chills and fever following amphotericin therapy.
    Febrile reactions may be decreased by the intravenous administration of small doses of adrenal corticosteroids, e.g. hydrocortisone. This may be administered just prior to or during amphotericin infusion. The dosage and duration of such corticosteroid therapy should be kept to a minimum.

    Amphotericin may be helpful in the treatment of American mucocutaneous leishmaniasis but is not the drug of choice for primary therapy.

    Amphotericin should not be used to treat the common forms of fungal infection which show only positive skin or serological tests.

    Pregnancy and Lactation


    Use amphotericin with caution in pregnancy.
    The safety of using amphotericin in pregnant women has not been established. Manufacturer advises that amphotericin should be used during pregnancy only if the possible benefits to be derived outweigh the potential risks involved.

    Systemic fungal infections have been successfully treated in pregnant women with conventional amphotericin without obvious effects on the foetus, but the number of cases reported has been small.
    Amphotericin crosses the placenta and exposure to the foetus and neonate may be prolonged by its retention in the placenta and other tissue.

    Schaefer (2007) advises that parenteral use during pregnancy should be restricted to dangerous disseminated mycoses.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Use amphotericin with caution in breastfeeding.
    It is not known whether amphotericin is excreted in human milk. As excretion of amphotericin in human milk is possible, and considering its potential toxicity, it should be used in nursing mothers only if the possible benefits to be derived outweigh the potential risks involved. In addition , it is prudent to advise a nursing mother to discontinue nursing.

    Amphotericin is highly protein bound with a large molecular weight and virtually unabsorbed orally (less than 9%) and is unlikely to be clinically significant to a breastfeeding infant.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Abnormal liver function tests
    Acute hepatic failure
    Acute renal failure
    Allergic alveolitis
    Anaphylactic reaction
    Anaphylactoid reaction
    Blurred vision
    Cardiac arrest
    Cardiac failure
    Cardiovascular toxicity
    Coagulation disorders
    Diabetes insipidus
    Epigastric pain
    Gastro-intestinal haemorrhage
    Hearing loss
    Local pain (injection site)
    Maculopapular rash
    Neurological effects
    Peripheral neuropathy
    Phlebitis (injection site)
    Pulmonary oedema
    Renal impairment
    Renal tubular acidosis
    Serum creatinine increased
    Skin exfoliation
    Stevens-Johnson syndrome
    Thrombophlebitis (injection site)
    Toxic epidermal necrolysis
    Ventricular fibrillation
    Weight loss


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: January 2014

    Reference Sources

    Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment, 2nd edition (2007) ed. Schaefer, C., Peters, P. and Miller, R. Elsevier, London.

    Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 9th edition (2011) ed. Briggs, G., Freeman, R. and Yaffe, S. Lippincott Williams & Wilkins, Philadelphia.

    Martindale: The Complete Drug Reference, 37th edition (2011) ed. Sweetman, S. Pharmaceutical Press, London.

    Medications and Mothers' Milk, 14th Edition (2010) Hale, T. Hale Publishing, Amarillo, Texas.

    Summary of Product Characteristics: Fungizone 50mg Powder for Sterile Concentrate. E.R. Squibb and Sons Ltd. Revised November 2016.

    NICE Evidence Services Available at: Last accessed: 04 September 2017

    US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
    Available at:
    Last revised: September 7, 2013
    Last accessed: December 11, 2013

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.